ATE237630T1 - Peptidartige stoffe, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung - Google Patents

Peptidartige stoffe, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung

Info

Publication number
ATE237630T1
ATE237630T1 AT96915086T AT96915086T ATE237630T1 AT E237630 T1 ATE237630 T1 AT E237630T1 AT 96915086 T AT96915086 T AT 96915086T AT 96915086 T AT96915086 T AT 96915086T AT E237630 T1 ATE237630 T1 AT E237630T1
Authority
AT
Austria
Prior art keywords
peptide
substances
therapeutic use
tnf release
inhibit metalloproteinases
Prior art date
Application number
AT96915086T
Other languages
English (en)
Inventor
Andrew Douglas Baxter
John Montana
David Alan Owen
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9509404.1A external-priority patent/GB9509404D0/en
Priority claimed from GBGB9525646.7A external-priority patent/GB9525646D0/en
Priority claimed from GBGB9607154.3A external-priority patent/GB9607154D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of ATE237630T1 publication Critical patent/ATE237630T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
AT96915086T 1995-05-10 1996-05-10 Peptidartige stoffe, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung ATE237630T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9509404.1A GB9509404D0 (en) 1995-05-10 1995-05-10 Compounds
GBGB9525646.7A GB9525646D0 (en) 1995-12-15 1995-12-15 Compounds
GBGB9607154.3A GB9607154D0 (en) 1996-04-04 1996-04-04 Compounds
PCT/GB1996/001135 WO1996035712A1 (en) 1995-05-10 1996-05-10 Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use

Publications (1)

Publication Number Publication Date
ATE237630T1 true ATE237630T1 (de) 2003-05-15

Family

ID=27267713

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96915086T ATE237630T1 (de) 1995-05-10 1996-05-10 Peptidartige stoffe, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung

Country Status (8)

Country Link
US (1) US5994293A (de)
EP (1) EP0824544B1 (de)
JP (1) JPH11504934A (de)
AT (1) ATE237630T1 (de)
AU (1) AU710502B2 (de)
CA (1) CA2217859A1 (de)
DE (1) DE69627483T2 (de)
WO (1) WO1996035712A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
HUP0003760A3 (en) * 1995-10-05 2001-05-28 Darwin Discovery Ltd Cambridge Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation, process for production thereof and their use
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
GB9624817D0 (en) * 1996-11-28 1997-01-15 British Biotech Pharm Metalloproteinase inhibitors
KR100385662B1 (ko) 1998-01-09 2003-05-28 화이자 인코포레이티드 매트릭스 메탈로프로테아제 억제제
JP2002528388A (ja) 1998-08-20 2002-09-03 イーライ リリー アンド カンパニー 環改変された環状ペプチドアナログ
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
WO2000040552A1 (en) * 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. Amidomalonamides and their use as inhibitors of matrix metalloproteinase
JP2004530647A (ja) * 2001-01-30 2004-10-07 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧治療用眼薬組成物
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
EP2931284B1 (de) 2012-12-14 2017-08-23 Merck Sharp & Dohme Corp. Bace-inhibitoren von iminothiadiazindioxiden

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006890A1 (en) * 1987-03-17 1988-09-22 Research Corporation Technologies, Inc. Synthetic inhibitors of mammalian collagenase
US5144043A (en) * 1988-06-15 1992-09-01 Centocor Cleavable bifunctional coupling agents
EP0455833B1 (de) * 1989-11-27 1995-04-19 Santen Pharmaceutical Co., Ltd. Aminosäurederivate
DE69309047T2 (de) * 1992-04-07 1997-09-11 British Biotech Pharm Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
WO1994009128A1 (en) * 1992-10-22 1994-04-28 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting vascular restenosis
CA2170158A1 (en) * 1993-08-23 1995-03-02 Roy A. Black Inhibitors of tnf-alpha secretion
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
DK0784629T3 (da) * 1994-10-05 1999-10-25 Darwin Discovery Ltd Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteaser

Also Published As

Publication number Publication date
AU5697796A (en) 1996-11-29
DE69627483D1 (de) 2003-05-22
DE69627483T2 (de) 2004-04-01
EP0824544A1 (de) 1998-02-25
CA2217859A1 (en) 1996-11-14
EP0824544B1 (de) 2003-04-16
AU710502B2 (en) 1999-09-23
WO1996035712A1 (en) 1996-11-14
JPH11504934A (ja) 1999-05-11
US5994293A (en) 1999-11-30

Similar Documents

Publication Publication Date Title
ATE278399T1 (de) Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen
MY120235A (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives
ATE266000T1 (de) Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
PL319503A1 (en) Peptide compounds and their therapeutic application as inhibitors
ATE226592T1 (de) Peptide, die metallproteinasen und die tnf- freisetzung hemmen, und ihre therapeutische verwendung
ATE237630T1 (de) Peptidartige stoffe, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
AU2003258196A1 (en) Process for the selection and evaluation of investment portfolio asset allocation strategies
IL135921A (en) Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
DK0827537T3 (da) Chromatin-regulator-gener
DK0944616T3 (da) Bicykliske arylcarboxamider og deres terapeutiske anvendelse
IL133952A0 (en) Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
IL123431A0 (en) Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (MMP) and/or tumour necrosis factor (TNF)
DE69831409D1 (de) Chalcon-derivate mit antiproliferativer aktivität
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
AP9701142A0 (en) 4,4-(Disubstituted) cyclohexan-1-ols monomers and related compounds.
PT1042288E (pt) Inibidores de tripeptidil peptidase
MY140504A (en) Statin-mmp inhibitor combinations
GB9723905D0 (en) Heterocyclic compounds having MMP and TNF inhibitory activity
PT1105388E (pt) Derivados de azabiciclo-heptano n-substituidos o seu fabrico e a sua utilizacao
MX9704733A (es) Monomeros de ciclohesan-1-ona 4,4-disubstituidos y compuestos relacionados.
MX9704739A (es) Monomeros de 3,3-(disustituido)ciclohexan-1-ona y compuestos relacionados.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties